| scholarly article | Q13442814 |
| P50 | author | Tatyana A. Shamliyan | Q54059092 |
| Wilbert S Aronow | Q67208280 | ||
| P2860 | cites work | Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial | Q27301948 |
| Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. | Q27687851 | ||
| The Cochrane Collaboration's tool for assessing risk of bias in randomised trials | Q27860509 | ||
| SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis | Q28076978 | ||
| Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis | Q28546797 | ||
| Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. | Q30244534 | ||
| Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials | Q30248634 | ||
| Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk | Q33601429 | ||
| Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus | Q33607764 | ||
| Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™) | Q33812170 | ||
| Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. | Q33901958 | ||
| Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 | ||
| Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study | Q35117192 | ||
| Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis | Q35157497 | ||
| Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis | Q35911236 | ||
| Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. | Q35968414 | ||
| Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes | Q36050559 | ||
| Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial | Q36402095 | ||
| Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial | Q37278239 | ||
| AHRQ series paper 1: comparing medical interventions: AHRQ and the effective health-care program | Q37286390 | ||
| Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes | Q37331262 | ||
| Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control | Q37351709 | ||
| AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews | Q37397185 | ||
| Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus | Q37468469 | ||
| Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program | Q37863325 | ||
| GRADE guidelines: 9. Rating up the quality of evidence | Q37908614 | ||
| Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication | Q38383475 | ||
| Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus | Q38408749 | ||
| Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus | Q38409388 | ||
| Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes | Q38555257 | ||
| Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians | Q39038688 | ||
| The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes | Q39674505 | ||
| 4B.02: THE SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR EMPAGLIFLOZIN REDUCES BLOOD PRESSURE AND MARKERS OF ARTERIAL STIFFNESS AND VASCULAR RESISTANCE IN TYPE 2 DIABETES. | Q40807876 | ||
| Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes | Q45231648 | ||
| Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes | Q45348074 | ||
| Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia | Q45442620 | ||
| Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. | Q45930171 | ||
| Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes | Q47581268 | ||
| Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension | Q50448714 | ||
| Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus. | Q51072174 | ||
| Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group study. | Q51305217 | ||
| Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. | Q51748822 | ||
| The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. | Q52373114 | ||
| Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. | Q53084508 | ||
| Post hoc power analysis: an idea whose time has passed? | Q54581210 | ||
| GRADE guidelines 6. Rating the quality of evidence—imprecision | Q57269328 | ||
| Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes | Q86042170 | ||
| Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin | Q86519614 | ||
| Mixed-effects modelling to quantify the effect of empagliflozin on renal glucose reabsorption in patients with type 2 diabetes | Q86575846 | ||
| Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes | Q86623452 | ||
| Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus | Q86932366 | ||
| Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes | Q87396359 | ||
| Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial | Q87809056 | ||
| Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial | Q88117871 | ||
| P433 | issue | 23 | |
| P921 | main subject | type 2 diabetes | Q3025883 |
| empagliflozin | Q5373824 | ||
| P304 | page(s) | 455 | |
| P577 | publication date | 2017-12-01 | |
| P1433 | published in | Annals of Translational Medicine | Q26842362 |
| P1476 | title | Comparative effectiveness and safety of empagliflozin on cardiovascular mortality and morbidity in adults with type 2 diabetes | |
| P478 | volume | 5 |
| Q97682163 | The association of sodium-glucose cotransporter 2 inhibitors with cancer: An overview of quantitative systematic reviews | cites work | P2860 |
Search more.